On Thursday, Gamal Esmat, member of the Egyptian National Committee on Viral Hepatitis told Aswat Masriya that around 1,7000 people had registered hours after online registration opened on the Health Ministry’s website.
19 September 2014 | Egyptian Streets
A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.
17 September 2014 | HIVandhepatitis.com
Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.
17 September 2014 | Infojustice
Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.
17 September 2014 | I-MAK
more than three dozen patient advocacy groups say the licensing deals do not go far enough, because the deals excludes many middle-income countries – such as Brazil, China, Turkey, Thailand and Ukraine – where governments and individuals may not be able to afford the Gilead drug. The patient groups are concerned the licenses will preclude the generic drug makers from selling lower-cost versions to those countries and potentially excluding millions of patients with hepatitis C from gaining access to treatment.
16 September 2014 | Pharmalot
Citing the 12-week treatment cost of $84,000, Oregon officials want to put strict new restrictions on access to the drug, especially for those in earlier stages of the disease. Commercial insurers already have some access rules, but are watching the state's battle closely.
16 September 2014 | The Oregonian
Gilead's licensing agreement with firms including India's Cipla Ltd and Ranbaxy Laboratories Ltd clears the way for the launch of a cheap generic version of the drug in 91 developing countries that make up 54 percent of the total global hepatitis burden.
15 September 2014 | Reuters
Added benefit for untreated and relapsed patients with unclear extent; major added benefit for non-responders; missing data for patients with HIV coinfection and genotype 4 patients.
10 September 2014 | German Institute for Quality and Efficiency in Health Care
Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.
09 September 2014 | Bloomberg
Two groups representing most of America’s HIV doctors have challenged moves by insurance companies to keep them from prescribing lifesaving hepatitis C medications. Insurers are requiring doctors prescribing sofosbuvir (Sovaldi), a once-daily pill for hepatitis C, to either be hepatologists or gastroenterologists. Those doctors specialize in issues related to the liver, which hepatitis C destroys. But hepatitis C is often transmitted along with HIV, so HIV doctors have long been treating their patients for both conditions.
09 September 2014 | Healthline